Literature DB >> 14665713

Molecular assays to profile 10 estrogen receptor beta isoform mRNA copy numbers in ovary, breast, uterus, and bone tissues.

Indira Poola1.   

Abstract

Estrogens regulate various biological processes in a diverse range of reproductive and nonreproductive tissues through two genetically distinct but structurally related high affinity nuclear receptors, the estrogen receptor alpha and beta (ERalpha and ERbeta). The physiological significance of the presence of two ERs that have redundant functions is not known. Several unique properties of ERbeta together with its distinct expression patterns are considered to be, in part, the basis for diverse functional actions of estrogens and opposing actions of selective estrogen receptor modulators (SERMs) in different tissues. To understand how relative expression levels of two ERs correlate to seemingly dissimilar actions of estrogens and SERMs, quantitative methods are required that can precisely measure the levels of every isoform. Previously, methods to quantify eight ERalpha isoforms have been described [Poola I. (2003) Anal. Biochem. 314, 217-226]. In this article, real-time PCRbased molecular assays are described that can distinguish and quantify as low as 100 copies of 10 ERbeta isoform mRNAs, the ERbeta1, ERbeta2, ERbeta4, ERbeta5, and ERbeta exon 2Delta, exon 3Delta, exon 4Delta, exon 5Delta, exon 6Delta, and exons 5-6Delta. Each isoform mRNA is quantified using a specific primer pair and a 5'FAM (carboxy-fluorescein)- and 3'TAMARA (6-carboxy tetraethyl-rhodamine)-labeled probe and in comparison with a standard curve constructed with known copy numbers of its respective reverse transcribed cRNA. The devised assays were applied to profile 10 ERbeta isoforms in four estrogen-sensitive tissues-ovary, breast, uterus, and bone. The sensitivity of detection of each isoform in these tissues varied from picograms to nanograms of reverse-transcribed total RNA depending on the isoform and the tissue. The results presented also show that each tissue has a distinct profile of 10 isoform mRNAs. Interestingly, ERalpha- negative breast cancer cell lines and tumors expressed significant amounts of ERbeta isoforms suggesting that mitogenic stimulation by estrogen exists in these tissues. Bone tissues expressed several isoforms, although wild type was not present. In addition to the assay development, evidence is presented to demonstrate for the first time that ERbeta4 and ERbeta5 are full length receptors, contrary to previous reports that they are short receptors of exon 7-8.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14665713     DOI: 10.1385/ENDO:22:2:101

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  31 in total

1.  A comparison of transcriptional activation by ER alpha and ER beta.

Authors:  S M Cowley; M G Parker
Journal:  J Steroid Biochem Mol Biol       Date:  1999 Apr-Jun       Impact factor: 4.292

Review 2.  Production and actions of estrogens.

Authors:  Christian J Gruber; Walter Tschugguel; Christian Schneeberger; Johannes C Huber
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

Review 3.  Breast cancer (2).

Authors:  J R Harris; M E Lippman; U Veronesi; W Willett
Journal:  N Engl J Med       Date:  1992-08-06       Impact factor: 91.245

4.  Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.

Authors:  G G Kuiper; B Carlsson; K Grandien; E Enmark; J Häggblad; S Nilsson; J A Gustafsson
Journal:  Endocrinology       Date:  1997-03       Impact factor: 4.736

5.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.

Authors:  K Paech; P Webb; G G Kuiper; S Nilsson; J Gustafsson; P J Kushner; T S Scanlan
Journal:  Science       Date:  1997-09-05       Impact factor: 47.728

6.  The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.

Authors:  J M Hall; D P McDonnell
Journal:  Endocrinology       Date:  1999-12       Impact factor: 4.736

7.  Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer.

Authors:  S A Fuqua; R Schiff; I Parra; W E Friedrichs; J L Su; D D McKee; K Slentz-Kesler; L B Moore; T M Willson; J T Moore
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

8.  Functionally active estrogen receptor isoform profiles in the breast tumors of African American women are different from the profiles in breast tumors of Caucasian women.

Authors:  Indra Poola; Robert Clarke; Robert DeWitty; LaSelle D Leffall
Journal:  Cancer       Date:  2002-02-01       Impact factor: 6.860

9.  Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern.

Authors:  E Enmark; M Pelto-Huikko; K Grandien; S Lagercrantz; J Lagercrantz; G Fried; M Nordenskjöld; J A Gustafsson
Journal:  J Clin Endocrinol Metab       Date:  1997-12       Impact factor: 5.958

10.  Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer.

Authors:  L C Murphy; E Leygue; Y Niu; L Snell; S-M Ho; P H Watson
Journal:  Br J Cancer       Date:  2002-12-02       Impact factor: 7.640

View more
  10 in total

1.  What's beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study.

Authors:  Emanuele Perrone; Riccardo Tudisco; Pia Clara Pafundi; Davide Guido; Alessandra Ciucci; Enrica Martinelli; Gian Franco Zannoni; Alessia Piermattei; Saveria Spadola; Giulia Ferrante; Claudia Marchetti; Giovanni Scambia; Anna Fagotti; Daniela Gallo
Journal:  Cancers (Basel)       Date:  2022-09-22       Impact factor: 6.575

2.  Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion.

Authors:  Yuet-Kin Leung; Hung-Ming Lam; Shulin Wu; Dan Song; Linda Levin; Liang Cheng; Chin-Lee Wu; Shuk-Mei Ho
Journal:  Endocr Relat Cancer       Date:  2010-06-25       Impact factor: 5.678

3.  Molecular constitution of breast but not other reproductive tissues is rich in growth promoting molecules: a possible link to highest incidence of tumor growths.

Authors:  Indira Poola; Jessy Abraham; Josephine J Marshalleck; Qingqi Yue; Sidney W Fu; Lokesh Viswanath; Nikhil Sharma; Russel Hill; Robert L Dewitty; George Bonney
Journal:  FEBS Lett       Date:  2009-08-19       Impact factor: 4.124

4.  The Cell Surface Estrogen Receptor, G Protein- Coupled Receptor 30 (GPR30), is Markedly Down Regulated During Breast Tumorigenesis.

Authors:  Indira Poola; Jessy Abraham; Aiyi Liu; Josephine J Marshalleck; Robert L Dewitty
Journal:  Breast Cancer (Auckl)       Date:  2008-04-17

5.  Estrogen receptors beta4 and beta5 are full length functionally distinct ERbeta isoforms: cloning from human ovary and functional characterization.

Authors:  Indira Poola; Jessy Abraham; Kate Baldwin; Alecia Saunders; Rakesh Bhatnagar
Journal:  Endocrine       Date:  2005-08       Impact factor: 3.925

6.  Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.

Authors:  Ameet K Mishra; Annelie Abrahamsson; Charlotta Dabrosin
Journal:  Oncotarget       Date:  2016-08-30

Review 7.  Estradiol Signaling at the Heart of Folliculogenesis: Its Potential Deregulation in Human Ovarian Pathologies.

Authors:  Stéphanie Chauvin; Joëlle Cohen-Tannoudji; Céline J Guigon
Journal:  Int J Mol Sci       Date:  2022-01-03       Impact factor: 5.923

8.  Estradiol Regulates mRNA Levels of Estrogen Receptor Beta 4 and Beta 5 Isoforms and Modulates Human Granulosa Cell Apoptosis.

Authors:  Alice Pierre; Anne Mayeur; Clémentine Marie; Victoria Cluzet; Jonathan Chauvin; Nelly Frydman; Michael Grynberg; Joelle Cohen-Tannoudji; Céline J Guigon; Stéphanie Chauvin
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

9.  Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer--a retrospective study.

Authors:  Raman Vinayagam; D Ross Sibson; Christopher Holcombe; Vijay Aachi; Michael Pa Davies
Journal:  BMC Cancer       Date:  2007-07-18       Impact factor: 4.430

10.  Estrogen receptor alpha (ER alpha) mRNA copy numbers in immunohistochemically ER alpha-positive-, and negative breast cancer tissues.

Authors:  Indira Poola; Qingqi Yue
Journal:  BMC Cancer       Date:  2007-03-28       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.